📷 Image: Wikimedia Commons / Kamlesh.legalaid
Business
Delhi High Court Dismisses Vimal Elaichi Firm’s Appeal Against Maharashtra FDA Notices to Actors
✍️ Mid-Day
🗓 15 Sep 2026, 10:16 AM
👁 10
The Delhi High Court rejected the plea filed by Vimal Elaichi, a spice company, challenging the Maharashtra Food and Drug Administration's notices issued to several actors.
The Delhi High Court, in a recent ruling, dismissed the appeal submitted by Vimal Elaichi, a spice manufacturer, against notices issued by the Maharashtra Food and Drug Administration (FDA) to a group of actors. The court held that the firm had not provided sufficient grounds to overturn the FDA’s directives.
Vimal Elaichi had argued that the notices, which required the actors to cease certain promotional activities, were arbitrary and infringed on their commercial rights. The company claimed that the FDA had overstepped its regulatory mandate.
The Maharashtra FDA had issued the notices in response to concerns about the actors’ use of the company’s spice products in public endorsements, citing potential health and safety violations. The agency maintained that the endorsements could mislead consumers about the product’s safety profile.
In its judgment, the Delhi High Court emphasized that the FDA’s regulatory powers extend to ensuring that promotional claims meet safety standards. The court found no legal basis for Vimal Elaichi to challenge the notices, thereby upholding the agency’s authority.
Vimal Elaichi had argued that the notices, which required the actors to cease certain promotional activities, were arbitrary and infringed on their commercial rights. The company claimed that the FDA had overstepped its regulatory mandate.
The Maharashtra FDA had issued the notices in response to concerns about the actors’ use of the company’s spice products in public endorsements, citing potential health and safety violations. The agency maintained that the endorsements could mislead consumers about the product’s safety profile.
In its judgment, the Delhi High Court emphasized that the FDA’s regulatory powers extend to ensuring that promotional claims meet safety standards. The court found no legal basis for Vimal Elaichi to challenge the notices, thereby upholding the agency’s authority.